Lecanemab
- Generic Name
- Lecanemab
- Brand Names
- Leqembi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1260393-98-3
- Unique Ingredient Identifier
- 12PYH0FTU9
- Background
Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology of Alzheimer’s disease. Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain with high selectivity to Aβ protofibrils. In clini...
- Indication
Lecanemab is indicated for the treatment of Alzheimer’s disease. Treatment with lecanemab should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
- Associated Conditions
- Alzheimer's Disease (AD)
- Associated Therapies
- -
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1906
- Registration Number
- NCT03887455
- Locations
- 🇺🇸
Emory University Cognitive Neurology Clinic & ADRC, Atlanta, Georgia, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 490
- Registration Number
- NCT01760005
- Locations
- 🇨🇦
UBC Hospital, Vancouver, British Columbia, Canada
🇺🇸University of Washington, Seattle, Washington, United States
🇫🇷CHU de Rouen - Hôpital Charles Nicolle, Rouen, Seine Maritime, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.